Implants and biodegradable tissue markers

Patent metadata

Field	Value
Publication number	US-2021069353-A1
Application number	US-202016999703-A
Country	US
Kind code	A1
Filing date	Aug 21, 2020
Priority date	Dec 15, 2009
Publication date	Mar 11, 2021
Grant date	—

Abstract

Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

First claim

1 .- 15 . (canceled)

16 . A method for radiation therapy comprising introducing a hydrogel spacer at a site between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation, wherein the hydrogel spacer comprises a polysaccharide and a radioopaque agent.

17 . The method of claim 16 , wherein the polysaccharide is hyaluronic acid.

18 . The method of claim 16 , wherein the radioopaque agent is a covalently attached radiopaque iodine agent.

19 . The method of claim 16 , wherein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland.

20 . The method of claim 16 , wherein the spacer provides a fiducial marker for administration of the therapeutic radiation.

21 . The method of claim 20 , further comprising visualizing the interface of the fiducial marker and the second tissue.

22 . The method of claim 21 , wherein the visualizing comprises computerized tomography or X-ray.

23 . The method of claim 16 , further comprising making a radiation plan based on a visualization of the hydrogel spacer, with the hydrogel spacer being in contact with the second tissue.

24 . The method of claim 23 , with the plan having a reduced uncertainty in target definition relative to a radiation plan made without the hydrogel spacer.

25 . The method of claim 16 , wherein the hydrogel spacer has a Hounsfield number of more than about 50.

26 . The method of claim 16 , wherein the hydrogel spacer, as placed in the tissue, has a volume between 1 and 40 ml.

27 . The method of claim 16 , further comprising visualizing margins of the hydrogel spacer with a machine selected from computerized tomography or X-ray.

28 . The method of claim 16 , further comprising a therapeutic agent in the hydrogel spacer.

29 . The method of claim 16 , with the radiopaque agent being present in the hydrogel spacer at a concentration of at least about 0.1% w/w.

30 . A method for radiation therapy comprising introducing a hydrogel spacer at a site between a first tissue location and a second tissue location, the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation, wherein the hydrogel spacer comprises hyaluronic acid and a covalently attached radiopaque agent.

31 . The method of claim 30 , herein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland.

32 . The method of claim 30 , wherein the hydrogel spacer, as placed in the tissue, has a volume between 1 and 40 ml.

33 . The method of claim 30 , wherein the hydrogel spacer has a Hounsfield number of more than about 50.

34 . The method of claim 30 , wherein the spacer provides a fiducial marker for administration of the therapeutic radiation.

35 . A method for radiation therapy comprising (a) introducing a hydrogel spacer at a site between a first tissue location and a second tissue location, the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation, wherein the hydrogel spacer comprises hyaluronic acid and a radiopaque agent and (b) visualizing margins of the hydrogel spacer with external imaging.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title